Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease.

Center for Management of Complex Chronic Care, Hines Veterans Affairs Hospital, Hines, Illinois 60141, USA.
Pharmacotherapy (Impact Factor: 2.2). 10/2009; 29(9):1039-53. DOI: 10.1592/phco.29.9.1039
Source: PubMed

ABSTRACT To evaluate outcomes associated with six treatment regimens with theophylline versus each regimen without theophylline in patients with chronic obstructive pulmonary disease (COPD).
Retrospective cohort study.
Veterans Affairs health care system.
A total of 183,573 patients aged 45 years or older who had a diagnosis of COPD and were receiving respiratory drug therapy.
Patients' treatment regimens were identified by using data from October 1, 2002-March 31, 2003, and patients were followed for events by using data from April 1, 2003-September 30, 2005. Data from October 1, 2001-September 30, 2002, were used to define the patients' baseline characteristics. Primary outcome measures were all-cause mortality, COPD exacerbations, and COPD-related hospitalizations. Two approaches were used: first, treatment assignment was based on drug therapy at baseline, and second, exposure was measured as a time-varying covariate. Treatment groups were stratified based on propensity to receive theophylline. Mortality was compared by using Cox proportional hazards models, and other outcomes were compared with use of negative binomial models. Comparisons were conducted within individual treatment regimens that were the same with the exception of theophylline. Patients treated with ipratropium plus theophylline (largest group) compared with those treated with ipratropium alone had a 1.11-fold increase in the risk of death (95% confidence interval [CI] 1.04-1.18). For each of the other regimens, the risk of mortality associated with theophylline was greater than that in the regimens without theophylline (hazard ratios [HRs] 1.17-1.31). In the time-varying exposure analysis, theophylline (HR 1.23, 95% CI 1.09-1.39) was associated with an increased mortality risk.
Patients receiving regimens that included theophylline had slightly increased risks of mortality, COPD exacerbations, and COPD hospitalizations compared with patients receiving the same regimens without theophylline. However, the benefits of theophylline on other factors, including symptoms, quality of life, and activities of daily living, were not measured. Clinicians should consider all of the potential benefits and harms associated with theophylline when making treatment recommendations.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic obstructive pulmonary disease (COPD) has been the only leading cause of death associated with a continuously increasing trend in the US over the past 30 years.
    SpringerPlus 01/2014; 3:359. DOI:10.1186/2193-1801-3-359
  • [Show abstract] [Hide abstract]
    ABSTRACT: The goals of management of COPD include reducing exposure to risk factors; improving lung function, exercise tolerance, and quality of life; and decreasing exacerbations and mortality. Pharmacologic treatments, such as inhaled β2-agonists, anticholinergics, and inhaled corticosteroids, are widely used to help achieve these goals. In addition to efficacy, medication safety is an important consideration in selecting COPD treatments. Clinical trials conducted in support of the regulatory review and approval process establish the general efficacy and tolerability of pharmacologic treatments for COPD, and these data are reflected in product labeling. Following approval, further research continues to provide more data with longer follow-up and in broader settings than feasible in clinical trials. These data add to our knowledge of the efficacy of medications. Understanding medication safety requires assessment of the quality and appropriateness of study design, as well as knowledge of study findings, and is of paramount importance in making sound clinical judgments in the treatment of patients with COPD. In recent years, a wealth of data on COPD medications has been published from different sources, including randomized clinical trials, meta-analyses, systematic reviews, and observational studies. This review discusses important considerations in interpreting data from different types of studies, summarizes the tolerability profile of COPD medications established in preapproval studies, and discusses new findings from more recent postapproval data.
    Chest 10/2013; 144(4):1357-1367. DOI:10.1378/chest.12-2438 · 7.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bronchodilators are central in the symptomatic treatment of chronic obstructive pulmonary disease (COPD), although there is often limited reversibility of airflow obstruction. Three classes of bronchodilators (β2-agonists, antimuscarinic agents, methylxanthines) are currently available, which can be used individually, or in combination with each other or inhaled corticosteroids. Novel classes of bronchodilators have proved difficult to develop. The muscarinic β2-agonist molecules approach likely provides the best opportunity to develop combinations that combine corticosteroids with dual-bronchodilator activities, and thus potentially achieve better efficacy than is apparent with the current combination products that dominate the treatment of COPD.
    Clinics in chest medicine 03/2014; 35(1):191-201. DOI:10.1016/j.ccm.2013.10.005 · 2.17 Impact Factor